Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model
/in Breast Cancer, Hyperthermia, International Publications /von 2017-03-13 / Sci Rep 2017 03;7:43961Short-course preoperative radiotherapy combined with chemotherapy, delayed surgery and local hyperthermia for rectal cancer: a phase II study
/in Colorectal Cancer, Hyperthermia, International Publications /von 2017-02-02 / Int J Hyperthermia 2017 Feb;:1-9Targeting therapy-resistant cancer stem cells by hyperthermia
/in Hyperthermia, International Publications /von 2017-02-02 / Int J Hyperthermia 2017 Jun;33(4):419-427Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis
/in Esophageal Carcinoma, Hyperthermia, International Publications /von 2017-01-25 / J Clin Pharm Ther 2017 Apr;42(2):155-164Regional hyperthermia combined with radiotherapy for esophageal squamous cell carcinoma with supraclavicular lymph node metastasis
/in Esophageal Carcinoma, Hyperthermia, International Publications /von 2017-01-17 / Oncotarget 2017 Jan;8(3):5339-5348In vitro comparison of conventional hyperthermia and modulated electro-hyperthermia
/in Hyperthermia, International Publications /von 2016-12-20 / Oncotarget 2016 Dec;7(51):84082-84092Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers
/in Esophageal Carcinoma, Hyperthermia, International Publications, Uterine Cancer /von 2016-11-01 / Cell Rep 2016 11;17(6):1621-1631Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy
/in Breast Cancer, Hyperthermia, International Publications /von 2016-10-04 / Oncotarget 2016 Oct;7(40):65042-65051Local hyperthermia in head and neck cancer: mechanism, application and advance
/in Hyperthermia, International Publications /von 2016-08-30 / Oncotarget 2016 Aug;7(35):57367-57378
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de